Differential Regulation of Resolution in Inflammation induced by Amyloid-β 42 and Lipopolysaccharides in Human Microglia
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Resolution of inflammation terminates the inflammatory response in physiological conditions and promotes restoration and healing of the tissue; however, failure in resolution results in chronic inflammation that may lead to disease. Chronic inflammation mediated by microglia is a feature of Alzheimer's disease (AD) and can be a pathogenic factor in which both treatment targets and diagnostic markers may be found. In addition, there is evidence that the resolution pathway is altered in AD. It is therefore relevant to investigate whether amyloid-β (Aβ) peptide, the major component of senile plaque in AD brain, may have a negative influence on components of the resolution cascade. In this pursuit, we exposed microglia to Aβ 42 , and with bacterial lipopolysaccharides (LPS) for comparison with a general infectious stimulus. Differential effects were observed: LPS upregulated components of the resolution pathway including the LXA 4 receptor/formyl peptide receptor 2 (ALX/FPR2) and phosphorylated 5-lipoxygenase (p-5-LOX), as well as cholinergic alpha 7 nicotinic receptor (α7nAChR) and peroxisome proliferator-activated receptor (PPAR)-δ whereas Aβ 42 had an opposite or insignificant effect. Our results indicate that LPS-induced changes in the microglia were conducive for resolution of inflammation, whereas these responses were absent or suppressed in microglia treated with Aβ 42 . Further studies may prove if Aβ 42 -induced dysfunction of resolution in microglia contributes to the impaired resolution in the AD brain, and if stimulation of microglial resolution constitutes a treatment strategy for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777
Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91209-9 · Cited by 1,693
Infection regulates pro-resolving mediators that lower antibiotic requirements
Chiang, N., Fredman, G., Bäckhed, F., Oh, S. F., Vickery, T., Schmidt, B. A., & Serhan, C. N. (2012) · Nature · doi:10.1038/nature11042 · Cited by 664
Godson, C., Mitchell, S., Harvey, K., Petasis, N. A., Hogg, N., & Brady, H. R. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.1663 · Cited by 638
Etminan, M., Gill, S., & Samii, A. (2003) · BMJ · doi:10.1136/bmj.327.7407.128 · Cited by 511
Resolution of inflammation is altered in Alzheimer's disease
Wang, X., Zhu, M., Hjorth, E., Cortés‐Toro, V., Eyjolfsdottir, H., Graff, C., Nennesmo, I., Palmblad, J., Eriksdotter, M., Sambamurti, K., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.024 · Cited by 301 · cited 7×
“postmortem brain tissue [15, 21].”
BackgroundResultInfluentialSelf-citationZhao, Y., Calon, F., Julien, C., Winkler, J. W., Petasis, N. A., Lukiw, W. J., & Bazan, N. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015816 · Cited by 243
Medeiros, R., Kitazawa, M., Passos, G. F., Baglietto-Vargas, D., Cheng, D., Cribbs, D. H., & LaFerla, F. M. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.01.051 · Cited by 163
Cited by
Serhan, C. N. (2017) · The FASEB Journal · doi:10.1096/fj.201601222r · Cited by 555
Layé, S., Nadjar, A., Joffre, C., & Bazinet, R. P. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014092 · Cited by 420
“RvD1 promotes anti-inflammatory phenotype in BV2 cells, enhancing Arg1 and Ym1 expression, IL-4 synthesis, and subsequent NFkB and PPARg activation and decreasing CD11b expression (Li et al., 2014; Zhu et al., 2015), via the regulation of miRNA expression (Rey et al., 2016).”
BackgroundChiang, N., & Serhan, C. N. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.03.005 · Cited by 324
The human microglial HMC3 cell line: where do we stand? A systematic literature review
Dello Russo, C., Cappoli, N., Coletta, I., Mezzogori, D., Paciello, F., Pozzoli, G., Navarra, P., & Battaglia, A. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1288-0 · Cited by 265
Serhan, C. N. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.03.001 · Cited by 257
Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase Aβ42 Phagocytosis
Zhu, M., Wang, X., Hjorth, E., Colas, R. A., Schroeder, L., Granholm, A.-C., Serhan, C. N., & Schultzberg, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9544-0 · Cited by 204
Self-citationSangineto, M., Ciarnelli, M., Cassano, T., Radesco, A., Moola, A., Bukke, V. N., Romano, A., Villani, R., Kanwal, H., Capitanio, N., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102846 · Cited by 142
Role of metabolic programming in the modulation of microglia phagocytosis by lipids
Nadjar, A. (2018) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2018.07.006 · Cited by 49
Metadata
- Authors
- Zhu, M., Wang, X., Schultzberg, M., & Hjorth, E.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2014-12-23
- Volume
- 43
- Issue
- 4
- Pages
- 1237-1250
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2125946419
- Cited by
- 45
- References
- 8
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.